Get the Stockscreener App
2.51
0.40%
-0.01
Indaptus Therapeutics Inc stock is traded at $2.51, with a volume of 22,333.
It is down -0.40% in the last 24 hours and up +0.40% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$2.52
Open:
$2.47
24h Volume:
22,333
Relative Volume:
0.03
Market Cap:
$4.41M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-1.3641
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-7.72%
1M Performance:
+0.40%
6M Performance:
-77.37%
1Y Performance:
+164.21%
1-Day Range:
$2.461
$2.52
1-Week Range:
$2.46
$3.06
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
2.52 | 4.41M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.70 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.49 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.09 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.04 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.03 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Three Indaptus Therapeutics board members signal planned resignations - Investing.com
Three Indaptus Therapeutics board members signal planned resignations By Investing.com - Investing.com India
Indaptus Therapeutics announces upcoming board leadership transition - TipRanks
Indaptus Therapeutics Announces Board Resignations - TradingView — Track All Markets
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 25.9% in December - Defense World
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Why did INDP stock gain 12% today? - MSN
Biotech Stocks To Keep An Eye OnDecember 24th - MarketBeat
Indaptus Therapeutics Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - marketscreener.com
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - The Globe and Mail
Indaptus Therapeutics secures $6 million investment, names new chairman By Investing.com - Investing.com Nigeria
Why Did INDP Stock Gain 12% Today? - Stocktwits
Indaptus Therapeutics stock falls after $6 million securities deal By Investing.com - Investing.com Nigeria
Indaptus Therapeutics stock falls after $6 million securities deal - Investing.com
Penny Stocks Worth Watching – December 25th - Defense World
What Does the Market Think About Indaptus Therapeutics Inc? - Benzinga
Indaptus Therapeutics Inc. (INDP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Indaptus Therapeutics Inc.: Are They Ready for Takeoff? - StocksToTrade
Indaptus Therapeutics, Inc.Common Stock (Nasdaq:INDP) Stock Quote - FinancialContent
Is It Too Late to Buy INDP Stock? - timothysykes.com
Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question - ts2.tech
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga
Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today - Sahm
Indaptus Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Trending Stocks Today | Indaptus Therapeutics Soars 52.9% Post-Market - 富途牛牛
Indaptus Therapeutics Inc appoints David Lazar as co-chief executive officer - marketscreener.com
Indaptus Therapeutics Signs Securities Purchase Agreement With David Lazar - TradingView — Track All Markets
INDP Files 8-K with SEC - Stock Titan
Indaptus Therapeutics, Inc. announced that it has received $6 million in funding - marketscreener.com
Indaptus Therapeutics, Inc. announced that it expects to receive $6 million in funding - marketscreener.com
Can Indaptus Therapeutics Inc. stock hit record highs again2025 Top Gainers & Precise Entry and Exit Recommendations - Улправда
How buybacks impact Indaptus Therapeutics Inc. stock valueTrade Analysis Summary & AI Forecast for Swing Trade Picks - Улправда
Breakout Move: Is Indaptus Therapeutics Inc stock attractive for hedge fundsJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - moha.gov.vn
Will Indaptus Therapeutics Inc. stock outperform value stocksShort Setup & Weekly High Potential Stock Alerts - DonanımHaber
How analysts rate Indaptus Therapeutics Inc. stock todayMarket Risk Report & Scalable Portfolio Growth Methods - Bölüm Sonu Canavarı
Is Indaptus Therapeutics Inc. stock a good choice for value investors2025 Valuation Update & Long Hold Capital Preservation Plans - ulpravda.ru
Published on: 2025-12-19 01:13:33 - moha.gov.vn
Indaptus Therapeutics Earnings Notes - Trefis
Indaptus Therapeutics (NASDAQ:INDP) Downgraded by Wall Street Zen to “Sell” - Defense World
Indaptus Therapeutics (NASDAQ:INDP) Rating Increased to Hold at Wall Street Zen - Defense World
Pullback Watch: How buybacks impact Indaptus Therapeutics Inc. stock valueMarket Weekly Review & Risk Controlled Stock Pick Alerts - moha.gov.vn
Nuvalent (NUVL) Receives a New Rating from Truist Financial - The Globe and Mail
Indaptus Therapeutics (INDP) Price Target Decreased by 60.00% to 10.20 - MSN
Volume spikes in Indaptus Therapeutics Inc. stock – what they meanEarnings Risk Summary & Smart Investment Allocation Insights - newser.com
Ranking Indaptus Therapeutics Inc. among high performing stocks via toolsTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Why Indaptus Therapeutics Inc. stock could see breakout soonPortfolio Return Report & Low Volatility Stock Recommendations - newser.com
Will Indaptus Therapeutics Inc. rebound enough to break evenJuly 2025 Recap & Expert Approved Momentum Ideas - newser.com
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):